ClinicalTrials.gg
CompletedNCT02899455Updated Oct 20, 2016

Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

A Phase 3 interventional study of HGP0904 and HGP0608 in Hypertension and Hyperlipidemia, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-10-20.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
104th of 186
146 · median 180
Started
2014
with 11 others
Phase 3
69 of 187
2 open now
Registered
138th of 187
by date
Lead sponsor
6 of 187
Hanmi Pharmaceutical Company Limited

Among the 187 studies testing amlodipine in Hypertension, this one is the 104th largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2014, is one of 69 in phase 3, and was the 138th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia

Read the detailed description

This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial to evaluate the efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia

03

Conditions studied

  • Hypertension
  • Hyperlipidemia

Keywords

  • Hypertension
  • Hyperlipidemia
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 ≤ age ≤ 75
  2. at Visit 1 1) BP: sitDBP ≥ 90mmHg 2) Cholesterol : LDL-C ≤ 250mg/dL, TG \< 400mg/dL
  3. at Visit 2 : after TLC (after 4weeks) 1) BP: 80 mmHg ≤ sitDBP \< 110mmHg 2) Cholesterol : following risk category (Cardiovascular Risk category) A : CHD risk factor 0 - 1, 160mg/dL ≤ LDL-C ≤ 250mg/dL B①: CHD risk factor≥2 and 10 year risk \<10%, 160mg/dL ≤ LDL-C ≤ 250mg/dL B②: CHD risk factor≥2 and 10 year risk =10-20%, 130mg/dL ≤ LDL-C ≤ 250mg/dL C : CHD/CHD risk equivalents* or 10 year risk>20 ,100mg/dL ≤ LDL-C ≤ 250mg/dL 3) TG \< 400mg/dL 4. Patients understood the contents and purpose of this trial and signed form

Exclusion criteria

Exclusion Criteria:

  1. At Visit 1, BP difference SBP ≥20mmHg or DBP ≥10mmHg
  2. Tolerance or Angiotensin II receptor blocker or HMG-CoA. reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy
  3. Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin
  4. CPK normal range ≥ 3times
  5. Uncontrolled primary hypothyroidism(TSH normal range ≥ 2 times)
  6. Renal disease or suspected renal disease (Scr ≥ 2mg/dL, or ALT≥2 times)
  7. Active gout or hyperuricemia(at Visit 1, uric acid > 9mg/dL)
  8. IDDM or uncontrolled diabetes mellitus (>9%)
  9. ventricular arrhythmia
  10. medical history

    • severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertension
    • encephalopathy, transient cerebral ischemic attack()
    • severe heart disease(heart failure of class III-IV), valvular disease of heart or myocardial infarction and unstable angina
    • angioplasty or coronary artery bypass graft(CABG) surgery within 6months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Experimental

    HGP0904 + HGP0608 + HGP0816, once daily

    Drug: HGP0904 · Drug: HGP0608 · Drug: HGP0816

  • Active comparator
    Active Comparator1

    HGP0904 placebo + HGP0608 + HGP0816, once daily

    Drug: HGP0608 · Drug: HGP0816 · Drug: HGP0904 Placebo

  • Active comparator
    Active Comparator2

    HGP0904 + HGP0608 + HGP0816 placebo, once daily

    Drug: HGP0904 · Drug: HGP0608 · Drug: HGP0816 Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in LDL-cholesterol at Week 8

    Time frame: baseline and 8 weeks

  2. Change from baseline in sitDBP at Week 8

    Time frame: baseline and 8 weeks

Secondary outcomes

  1. Percentage change from baseline in LDL cholesterol at Week 4

    Time frame: baseline and 4 weeks

  2. Percentage change from baseline in Total cholesterol, HDL cholesterol, Triglyceride at Week 4,8

    Time frame: baseline, 4weeks and 8 weeks

  3. Change from baseline in sitDBP at Week 4

    Time frame: baseline and 4weeks

  4. Change from baseline in sitSBP at week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

  5. Proportion of subjects achieving LDL-cholesterol goals by cardiovascular risk category at Week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

  6. Proportion of subjects achieving Blood Pressure control by cardiovascular risk category at Week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

  7. Proportion of subjects achieving LDL-cholesterol goals and Blood Pressure control by cardiovascular risk category at Week 4, 8

    Time frame: baseline, 4weeks and 8 weeks

07

Study locations

1 site
  • 23 institutions including Samsung Medical Center
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Lee HY, Kim SY, Choi KJ, Yoo BS, Cha DH, Jung HO, Ryu DR, Choi JH, Lee KJ, Park TH, Oh JH, Kim SM, Choi JY, Kim KH, Shim J, Kim WS, Choi SW, Park DG, Song PS, Hong TJ, Rhee MY, Rha SW, Park SW. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. Clin Ther. 2017 Dec;39(12):2366-2379. doi: 10.1016/j.clinthera.2017.10.013. Epub 2017 Nov 14. PubMed 29150250 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2016
First posted
Sep 14, 2016
Start
Jul 2014
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Oct 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02899455
Responsible party
Sponsor
First posted
Sep 14, 2016
Start date
Jul 2014
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Oct 20, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · HGP0816

Start the discussion